Tag Archives: Deals

Deals Don't Need Science To Be A Success

By Guest Blogger | Published: September 21, 2011
Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
Posted in Global, Guest Blog, Strategy | Also tagged , , , | 2 Comments

Is Sanofi Right to Bank on MS Drug?

By Julian Upton | Published: February 23, 2011
Newswires have long been waiting for Sanofi-Aventis to officially announce its acquisition of US biotech company Genzyme, but what few analysts were expecting is just how much the transaction would hedge on one potentially controversial product. As the focus of Sanofi’s contingent value rights (CVR) approach, Genzyme’s multiple sclerosis treatment Lemtrada (also sold as Campath [...]
Posted in Safety, Strategy, pricing | Also tagged , , , , | 1 Comment

MedImmune Bets Its Fate on “Biobetters”

By Walter Armstrong | Published: September 9, 2010
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy | Also tagged , , , , , | 1 Comment

M&A Round-up • 3/25/2009

By George Koroneos | Published: March 25, 2009
The latest round of merger and acquisition activities courtesy of our friends at Pharm Exec Europe: • Just days after its purchase of Genentech, Roche has made another acquisition, albeit a much smaller one, of the German firm Innovatis. Roche will pay EUR 15 million for the cell analytics company. • Oxford Gene Technology (OGT) is to [...]
Posted in Deals | Also tagged , , , , , , , , , | Leave a comment

Pfizer to Buy Wyeth for $68 Billion

By George Koroneos | Published: January 26, 2009
Pfizer made it official this morning. The pharma giant acquired Wyeth for $50.19 a share or $68 billion in cash and stocks, and news of the merger sent ripples through the pharma industry: Pfizer Broadens Beyond Pills with $68 Billion Wyeth Buy: Pfizer has agreed to acquire Wyeth in a $68 billion deal that’s the largest [...]
Posted in Deals | Also tagged , , , | Leave a comment